A biosimilar is a biologic drug that is highly similar, but not identical, to an already approved biologic drug, i.e. the reference...

This month, in Allergan USA, Inc. v. MSN Laboratories Private Ltd., the Federal Circuit added to the ongoing patent-family drama...

The United States Patent and Trademark Office (USPTO) has proposed changes to terminal disclaimer rules that could significantly...

mRNA-Based Vaccine and Other Therapeutics mRNA-based vaccines have become one of the most discussed technologies both inside and outside...

Earlier this week, the U.S. Patent and Trademark Office (USPTO) issued a request for public comment regarding the impact of artificial...

Copyright attorneys eagerly anticipated the U.S. Supreme Court's fair use opinion in Andy Warhol Foundation for the Visual Arts, Inc. v....

The district court in Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc., Civil Action No. 20-430-RGA (D. Del.) was asked...

The U.S. Patent & Trademark Office (USPTO) has issued new guidance affirming that its existing rules regarding user accounts, access to...

The Federal Circuit recently reversed a PTAB obviousness finding because it found no motivation to combine features of the two cited...

Only “natural persons” can be named “inventors” on U.S. patents. But last month, the U.S. Patent and Trademark Office (USPTO) issued...

In alignment with both the U.S. Patent & Trademark Office's determination in 2020 (affirmed by the U.S. Court of Appeals for the Federal...

Manufacturers of pharmaceuticals, biologics, and herbicides, as well as companies in virtually every industry, routinely make statements...